David Cappellen

6PUBLICATIONS
41CO-AUTHORS
Molecular targetsRegenerative medicine (incl. stem cells)Predictive and prognostic markersHaematological tumoursEpigenetics (incl. genome methylation and epigenomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 10, 2026
Single-cell multiplex approaches deeply map ON-target CRISPR-genotoxicity and reveal its mitigation by palbociclib and long-term engraftment.

Julian Boutin, Sabrina Fayet, Victor Marin

|Feb 03, 2025
Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile.

Audrey Burban, Cloe Tessier, Mathieu Larroquette

|Jul 10, 2023
Cell cycle arrest and p53 prevent ON-target megabase-scale rearrangements induced by CRISPR-Cas9.

G Cullot, J Boutin, S Fayet

|Dec 24, 2021
Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy.

Léa Dousset, Florence Poizeau, Caroline Robert

|Sep 28, 2021
Hepatocellular adenoma with a double mutation HNF1A and IDH1 in a patient with Ollier disease.

David Cappellen, Isabelle Catry-Thomas, Claire Castain

|Aug 14, 2021
CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity in hematopoietic cells.

J Boutin, J Rosier, D Cappellen

Pageof 1

Frequent Collaborators

3 joint publications

Julian Boutin

3 joint publications

Jean-Philippe Merlio

3 joint publications

François Moreau-Gaudry

2 joint publications

P Pennamen